Immediate Impact
73 standout
Citing Papers
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
2025 Standout
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
2025 Standout
Works of D. J. Harman being referenced
Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review
2017
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| D. J. Harman | 411 | 246 | 288 | 44 | 747 | |
| Francesca Iannuzzi | 195 | 236 | 215 | 32 | 701 | |
| Yutaka Komiya | 333 | 309 | 314 | 28 | 714 | |
| P. Parisi | 148 | 487 | 236 | 30 | 780 | |
| Joseph Mazur | 138 | 94 | 34 | 35 | 769 | |
| Chen Jh | 112 | 9 | 74 | 80 | 984 | |
| David Van Buren | 38 | 167 | 32 | 24 | 777 | |
| Kazuyoshi Kumagai | 93 | 139 | 57 | 50 | 929 | |
| Xiaoning Wu | 537 | 7 | 404 | 72 | 933 | |
| Takeshi Oda | 121 | 177 | 9 | 79 | 738 | |
| Shanshan Weng | 81 | 179 | 11 | 85 | 687 |
All Works
Login with ORCID to disown or claim papers
Loading papers...